Latest Pharma News
Follow the latest pharma news from India and the wider pharmaceutical industry. This section highlights major headlines, breaking developments, and important daily updates.
-
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million JobsOhio
-
Next-gen platforms poised to redefine crowded hereditary angioedema landscape
Next-gen platforms poised to redefine crowded hereditary angioedema landscape The Pharma Letter
-
Oak Hill Bio raises $32.5 million Series A financing
Oak Hill Bio raises $32.5 million Series A financing The Pharma Letter
-
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease Pharmaceutical Technology
-
Meiji Seika Pharma Invests in Global Health Fund
Meiji Seika Pharma Invests in Global Health Fund Grocery Trade News
Regulatory Updates
Track pharmaceutical regulatory updates, policy changes, and compliance-related news. This section is useful for staying informed about approvals, guidelines, and official announcements.
-
Elite Pharmaceuticals Files ANDA with FDA for Generic Anticoagulant Drug Targeting $26 Billion Market 1
Elite Pharmaceuticals Files ANDA with FDA for Generic Anticoagulant Drug Targeting $26 Billion Market 1 Minichart
-
Implications of Pediatric Inhaled Insulin Approval
Implications of Pediatric Inhaled Insulin Approval PharmTech.com
-
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy STT Info
-
Elite Pharmaceuticals (OTCBB: ELTP) targets $26B anticoagulant market with new ANDA
Elite Pharmaceuticals (OTCBB: ELTP) targets $26B anticoagulant market with new ANDA Stock Titan
-
Generic shot at $26B blood thinner: Elite Pharma files with FDA
Generic shot at $26B blood thinner: Elite Pharma files with FDA Stock Titan
Drug Approvals
Read about new drug approvals, product clearances, and important authorisations. This section covers medicines entering the market and other notable approval milestones.
-
This new drug could change how we treat one of the deadliest cancers
This new drug could change how we treat one of the deadliest cancers PBS
-
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial USA Today
-
FDA delays cost Americans trillions and slow lifesaving drugs, new report says
FDA delays cost Americans trillions and slow lifesaving drugs, new report says WFIN
-
The FDA Is Now Fast-Tracking Magic Mushroom Drugs for Depression, Joe Rogan Claims Credit for the Idea
The FDA Is Now Fast-Tracking Magic Mushroom Drugs for Depression, Joe Rogan Claims Credit for the Idea International Business Times UK
-
Zydus Saroglitazar Gets US FDA Priority Review
Zydus Saroglitazar Gets US FDA Priority Review Passionate In Marketing
Clinical and Research Updates
Explore clinical trial news, research findings, and developments in pharmaceutical science. This section focuses on innovation, studies, and progress in drug development.
-
Experimental pancreatic cancer drug offers new hope in major trial
Experimental pancreatic cancer drug offers new hope in major trial ABC30 Fresno
-
COCP: Presentation Highlights CDI-988
COCP: Presentation Highlights CDI-988 Zacks Small Cap Research
-
New pancreatic cancer pill may revolutionize treatment for the deadly disease, experts say
New pancreatic cancer pill may revolutionize treatment for the deadly disease, experts say PhillyVoice
-
ASCO 2026 Cancer Breakthroughs: Pancreatic Survival Doubles, Chemo Spared in Breast
ASCO 2026 Cancer Breakthroughs: Pancreatic Survival Doubles, Chemo Spared in Breast Tech Times
-
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial USA Today
Industry Events
Discover pharma conferences, exhibitions, seminars, and industry events in India. This section helps readers keep track of sector gatherings and professional events.
-
Dr. Ashish Jha Headlines ConV2X Smart Technology Transformation Summit - NYC Oct 2026
Dr. Ashish Jha Headlines ConV2X Smart Technology Transformation Summit - NYC Oct 2026 WebWire
-
Summit Therapeutics (SMMT) posts positive ASCO 2026 ivonescimab survival and response data
Summit Therapeutics (SMMT) posts positive ASCO 2026 ivonescimab survival and response data Stock Titan
-
Short on growth ideas, Putin hosts fifth wartime 'Russian Davos'
Short on growth ideas, Putin hosts fifth wartime 'Russian Davos' Reuters
-
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China BioSpace
-
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 Yahoo Finance
Company Announcements
View company announcements including results, partnerships, expansions, and strategic updates. This section offers insights into the latest moves by pharma businesses.
-
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing Investing.com UK
-
Olenox Industries Completes Acquisition of CS Digital Ventures, Launching a Vertically Integrated, Gas-Powered Platform for Energy-Intensive Data Centers and Next-Generation Compute
Olenox Industries Completes Acquisition of CS Digital Ventures, Launching a Vertically Integrated, Gas-Powered Platform for Energy-Intensive Data Centers and Next-Generation Compute ACCESS Newswire
Market and Sector Headlines
Stay informed on market trends, sector performance, and broader industry headlines. This section gives a wider view of the forces shaping the pharmaceutical market.
-
Starcoin Group Faces 18-Month Deadline to Restore Compliance or Risk Delisting
Starcoin Group Faces 18-Month Deadline to Restore Compliance or Risk Delisting TipRanks
-
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): focus on Bristol Myers deal and China A-share
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): focus on Bristol Myers deal and China A-share AD HOC NEWS
-
Sawai Group Holdings stock (JP3511800006): Japanese generics specialist in focus after recent tradin
Sawai Group Holdings stock (JP3511800006): Japanese generics specialist in focus after recent tradin AD HOC NEWS
-
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma AOL.com
-
Norway stocks higher at close of trade; Oslo OBX up 0.55%
Norway stocks higher at close of trade; Oslo OBX up 0.55% Investing.com
Policy and Government Initiatives
This section covers new regulations, industry support measures, and reforms that affect manufacturing, pricing, and compliance. It is also useful for following government schemes that encourage domestic production, exports, and research-led growth.
-
'Visa rules are getting tougher': IPS officer flags Indians’ behaviour abroad, warns of stricter visa rules
'Visa rules are getting tougher': IPS officer flags Indians’ behaviour abroad, warns of stricter visa rules Moneycontrol.com
-
India-Oman CEPA comes into force; exports seen rising to $7 billion within 2 years
India-Oman CEPA comes into force; exports seen rising to $7 billion within 2 years Moneycontrol.com
-
India-Oman CEPA Comes Into Force, Set to Boost Trade, Investment and Job Creation
India-Oman CEPA Comes Into Force, Set to Boost Trade, Investment and Job Creation India Business Trade
-
India bonds slip ahead of RBI policy as war risks lift oil
India bonds slip ahead of RBI policy as war risks lift oil The Economic Times
-
Haryana inks Rs. 1.10 lakh crore MoUs, targets Rs. 5 lakh crore investment
Haryana inks Rs. 1.10 lakh crore MoUs, targets Rs. 5 lakh crore investment Tehelka